Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Pathogenesis of Superior Limbic Keratoconjunctivitis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2005 by National Taiwan University Hospital.
Recruitment status was:  Recruiting
Information provided by:
National Taiwan University Hospital Identifier:
First received: September 12, 2005
Last updated: November 25, 2005
Last verified: June 2005
Superior limbic keratoconjunctivitis (SLK) was first described in detail as a clinical entity by Frederick Theodore in 1963. The clinical picture of SLK is well documented, but the etiology is still unknown. This project will be conducted into through two parts: one is to investigate the presentation of chemokine receptors on mast cell and matrix metalloproteinases on fibroblasts by immunohistochemistry method from the pathological specimens of SLK patients who received conjunctiva resection as the treatment. The other part is to investigate the mRNA level of those chemokine receptors via reverse transcription - polymerase chain reaction from the conjunctiva collecting form SLK patients.

Superior Limbic Keratoconjunctivitis

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Cross-Sectional
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by National Taiwan University Hospital:

Estimated Enrollment: 10
Study Start Date: July 2005
Estimated Study Completion Date: June 2006
  Show Detailed Description


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Superior limbic keratoconjunctivitis patients who receive conjunctiva resection

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00167050

Contact: Fung-Rong Hu, MD 886-2-23123456 ext 5189
Contact: Yi-Chen Sun, MD 886-968195019

National Taiwan University Hospital Recruiting
Taipei, Taiwan
Contact: Fung-Rong Hu, MD    886-2-23123456 ext 5189   
Contact: Yi-Chen Sun, MD    886-968195019   
Principal Investigator: Fung-Rong Hu, MD         
Sponsors and Collaborators
National Taiwan University Hospital
Principal Investigator: Fung-Rong Hu, MD National Taiwan University Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00167050     History of Changes
Other Study ID Numbers: 9461700634
Study First Received: September 12, 2005
Last Updated: November 25, 2005

Additional relevant MeSH terms:
Conjunctival Diseases
Eye Diseases
Corneal Diseases processed this record on April 28, 2017